BACKGROUND AND AIMS: Previous studies have suggested that increased body iron stores and heterozygosity for haemochromatosis are associated with an increased risk of colorectal carcinoma. The aim of this study is to determine if there is an association between (i) colorectal carcinoma and heterozygosity for the Cys282Tyr mutation of the haemochromatosis gene (HFE) and (ii) this mutation and tumour site or stage. METHODS: Two hundred and twenty-nine unselected patients (127 males, 102 females, mean age 68.0 years) with sporadic colorectal carcinoma and 228 controls (145 males, 83 females, mean age 69.7 years) were studied. DNA was tested for the presence of the Cys282Tyr mutation by digestion with Rsa1 and fragments separated by electrophoresis. RESULTS: Twenty-one patients with colorectal cancer and 23 control subjects were heterozygous for the Cys282Tyr mutation of HFE (relative risk 0.90). There was no association between heterozygosity of the Cys282Tyr mutation and tumour site or stage. CONCLUSIONS: Heterozygosity for the Cys282Tyr mutation of HFE does not appear to be a risk factor for colorectal carcinoma.
BACKGROUND AND AIMS: Previous studies have suggested that increased body iron stores and heterozygosity for haemochromatosis are associated with an increased risk of colorectal carcinoma. The aim of this study is to determine if there is an association between (i) colorectal carcinoma and heterozygosity for the Cys282Tyr mutation of the haemochromatosis gene (HFE) and (ii) this mutation and tumour site or stage. METHODS: Two hundred and twenty-nine unselected patients (127 males, 102 females, mean age 68.0 years) with sporadic colorectal carcinoma and 228 controls (145 males, 83 females, mean age 69.7 years) were studied. DNA was tested for the presence of the Cys282Tyr mutation by digestion with Rsa1 and fragments separated by electrophoresis. RESULTS: Twenty-one patients with colorectal cancer and 23 control subjects were heterozygous for the Cys282Tyr mutation of HFE (relative risk 0.90). There was no association between heterozygosity of the Cys282Tyr mutation and tumour site or stage. CONCLUSIONS: Heterozygosity for the Cys282Tyr mutation of HFE does not appear to be a risk factor for colorectal carcinoma.
Authors: Agustin Castiella; Fernando Múgica; Eva Zapata; Leire Zubiaurre; Arantxa Iribarren; M Dolores de Juan; Luis Alzate; Ines Gil; Gregorio Urdapilleta; Pedro Otazua; José Ignacio Emparanza Journal: Tumour Biol Date: 2015-04-09
Authors: Anita C G Chua; Borut Klopcic; Ian C Lawrance; John K Olynyk; Debbie Trinder Journal: World J Gastroenterol Date: 2010-02-14 Impact factor: 5.742
Authors: Nicholas J Osborne; Lyle C Gurrin; Katrina J Allen; Clare C Constantine; Martin B Delatycki; Christine E McLaren; Dorota M Gertig; Gregory J Anderson; Melissa C Southey; John K Olynyk; Lawrie W Powell; John L Hopper; Graham G Giles; Dallas R English Journal: Hepatology Date: 2010-04 Impact factor: 17.425
Authors: Douglas A Corley; Ai Kubo; T R Levin; Gladys Block; Laurel Habel; Gregory J Rumore; Charles Quesenberry; Patricia Buffler Journal: Dig Dis Sci Date: 2008-05-10 Impact factor: 3.199
Authors: Elizabeth H Ruder; Sonja I Berndt; Anne M J Gilsing; Barry I Graubard; Laurie Burdett; Richard B Hayes; Joel L Weissfeld; Leah M Ferrucci; Rashmi Sinha; Amanda J Cross Journal: Carcinogenesis Date: 2014-02-17 Impact factor: 4.944
Authors: Nathan R Jones; Joseph H Ashmore; Sang Y Lee; John P Richie; Philip Lazarus; Joshua E Muscat Journal: Cancers (Basel) Date: 2015-12-09 Impact factor: 6.639